Cumberland Pharmaceuticals Announces Presentation of Caldolor Data at American Academy of Pain Management Meeting

NASHVILLE, Tenn., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- *Cumberland Pharmaceuticals Inc.* (Nasdaq: CPIX) announced today that data from two key clinical trials for Caldolor(R), an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

Data from the following clinical trials of Caldolor will be displayed in poster presentations on Saturday, October 10, 2009, from 1:30-3:00 pm Mountain Time:

- A phase III dose ranging pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults" will be presented by principal author, Stephen R. Southworth, MD, FACS (study 008A, poster #49).

- A phase III abdominal hysterectomy pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults," authored by Peter Kroll, M.D., will be presented by co-author Laura Meadows, BC, CRCC (study 008B, poster #50).

In conjunction with the presentations, copies of the posters will be available on Cumberland's website at http://investor.shareholder.com/cpix/events.cfm, or by contacting the Company at 615-255-0068.

SOURCE: Cumberland Pharmaceuticals Inc.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States, and has now completed the commercial launch of that product. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company recently completed the initial public offering of its common stock.

For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

http://www.cumberlandpharma.com/